Sino Biopharm has a good financial position. As of December 2024, it has CNY 9.6 billion in cash on hand and CNY 9.6 billion in debt. Total debt outstanding is 14.7% of its total assets. Its capital ...

Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address ... a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment ...

The approval of Libtayo (cemiplimab) in advanced NSCLC is for first-line treatment of patients with 50% or more PD-L1 expression and no EGFR, ALK or ROS1 aberrations, taking the drug into a large ...

The study “continues to confirm that RET fusions are clinically targetable alterations, placing them in the company of activating EGFR/ALK/ROS1 alterations,” said Drilon. “We are encouraged ...

ROS1, and ALK kinases; APG-5918, an orally available and selective embryonic ectoderm development inhibitor; APG-265, a MDM2 protein degrader; and UBX1967/1325, which are Bcl-2 inhibitors.

This errant process, called ALK rearrangement, can lead to unchecked cell growth and cancer development. The ROS1 gene is involved in cell growth and differentiation. Like ALK, ROS1 can be erroneously ...

DelveInsight's "VITRAKVI Market Size, Forecast, and Market Insight Report" highlights the details around VITRAKVI, a TRK, ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Radiomics ...

During a Community Case Forum event in partnership with the Texas Society of Clinical Oncology, Natalie Vokes, MD, discussed ...

VITRAKVI has strong market potential as a first-in-class TRK inhibitor for patients with NTRK gene fusion-positive cancers, regardless of tumor type. The growing adoption of precision oncology ...

1 Day ALK 3.40% DJIA 0.92% S&P 500 1.08% Transportation/Logistics 0.57% ...